187 related articles for article (PubMed ID: 37726578)
21. A prospective prognostic signature for pancreatic adenocarcinoma based on ubiquitination-related mRNA-lncRNA with experimental validation in vitro and vivo.
Wang Z; Yuan Q; Chen X; Luo F; Shi X; Guo F; Ren J; Li S; Shang D
Funct Integr Genomics; 2023 Aug; 23(3):263. PubMed ID: 37540295
[TBL] [Abstract][Full Text] [Related]
22. System analysis based on the pyroptosis-related genes identifies GSDMC as a novel therapy target for pancreatic adenocarcinoma.
Yan C; Niu Y; Li F; Zhao W; Ma L
J Transl Med; 2022 Oct; 20(1):455. PubMed ID: 36199146
[TBL] [Abstract][Full Text] [Related]
23. Identify potential prognostic indicators and tumor-infiltrating immune cells in pancreatic adenocarcinoma.
Shi T; Gao G
Biosci Rep; 2022 Feb; 42(2):. PubMed ID: 35083488
[TBL] [Abstract][Full Text] [Related]
24. Quantitative Assessment of CMTM6 in the Tumor Microenvironment and Association with Response to PD-1 Pathway Blockade in Advanced-Stage Non-Small Cell Lung Cancer.
Zugazagoitia J; Liu Y; Toki M; McGuire J; Ahmed FS; Henick BS; Gupta R; Gettinger SN; Herbst RS; Schalper KA; Rimm DL
J Thorac Oncol; 2019 Dec; 14(12):2084-2096. PubMed ID: 31605795
[TBL] [Abstract][Full Text] [Related]
25. Identification of tumor antigens and immune subtypes of pancreatic adenocarcinoma for mRNA vaccine development.
Huang X; Zhang G; Tang T; Liang T
Mol Cancer; 2021 Mar; 20(1):44. PubMed ID: 33648511
[TBL] [Abstract][Full Text] [Related]
26.
Kuang W; Wang X; Ding J; Li J; Ji M; Chen W; Wang L; Yang P
Front Immunol; 2022; 13():805311. PubMed ID: 35154122
[TBL] [Abstract][Full Text] [Related]
27. Molecular and immunological characteristics of patients with CMTM6 low expression colorectal cancer.
Lu ZM; Pan SL; Yuan WL; Feng JL; Tian D; Shang XQ
Medicine (Baltimore); 2023 Dec; 102(50):e36480. PubMed ID: 38115316
[TBL] [Abstract][Full Text] [Related]
28. Analysis and validation of the potential of the MYO1E gene in pancreatic adenocarcinoma based on a bioinformatics approach.
Liu S; Liu P; Fei X; Zhu C; Hou J; Wang X; Pan Y
Oncol Lett; 2023 Jul; 26(1):285. PubMed ID: 37274465
[TBL] [Abstract][Full Text] [Related]
29. Quantitative analysis of CMTM6 expression in tumor microenvironment in metastatic melanoma and association with outcome on immunotherapy.
Martinez-Morilla S; Zugazagoitia J; Wong PF; Kluger HM; Rimm DL
Oncoimmunology; 2020 Dec; 10(1):1864909. PubMed ID: 33457084
[TBL] [Abstract][Full Text] [Related]
30. CMTM6 and CMTM4 as two novel regulators of PD-L1 modulate the tumor microenvironment.
Zhang T; Yu H; Dai X; Zhang X
Front Immunol; 2022; 13():971428. PubMed ID: 35958549
[TBL] [Abstract][Full Text] [Related]
31. LncRNAs-Regulated High Expression of LAMC2 Reveals a Prognostic and Immunological Value in Pancreatic Adenocarcinoma.
Liu J; Wang M; Wang M; Wang F; Zhang B
Biochem Genet; 2024 Feb; 62(1):485-503. PubMed ID: 37382751
[TBL] [Abstract][Full Text] [Related]
32. Relationship between a 7-mRNA signature of the pancreatic adenocarcinoma microenvironment and patient prognosis (a STROBE-compliant article).
He QL; Jiang HX; Zhang XL; Qin SY
Medicine (Baltimore); 2020 Jul; 99(29):e21287. PubMed ID: 32702921
[TBL] [Abstract][Full Text] [Related]
33. Suppression of Tumor or Host Intrinsic CMTM6 Drives Antitumor Cytotoxicity in a PD-L1-Independent Manner.
Long Y; Chen R; Yu X; Tong Y; Peng X; Li F; Hu C; Sun J; Gong L
Cancer Immunol Res; 2023 Feb; 11(2):241-260. PubMed ID: 36484740
[TBL] [Abstract][Full Text] [Related]
34. Comprehensive pan-cancer analysis of role of GPRASP1, associated with clinical outcomes, immune microenvironment, and immunotherapeutic efficiency in pancreatic cancer.
Du J; Chen Y; Liu G; Zeng Q; Zhou N; Du D
Pathol Res Pract; 2023 Mar; 243():154374. PubMed ID: 36801507
[TBL] [Abstract][Full Text] [Related]
35. Prognostic Value and the Immune Microenvironment-associated Role of
Song Y; Wang Y; Yu T; He Y; Wang C; Wang F; Zhou Y
Anticancer Res; 2023 Dec; 43(12):5393-5408. PubMed ID: 38030175
[TBL] [Abstract][Full Text] [Related]
36. CMTM6, a potential immunotherapy target.
Liang J; Li S; Li W; Rao W; Xu S; Meng H; Zhu F; Zhai D; Cui M; Xu D; Cai J; Zhang B
J Cancer Res Clin Oncol; 2022 Jan; 148(1):47-56. PubMed ID: 34783871
[TBL] [Abstract][Full Text] [Related]
37. Molecular subtyping based on TRP family and prognostic assessment for TRP-associated lncRNAs in pancreatic adenocarcinoma.
Li L; Xiao Z; He P; Zou W; Deng Z; Zhang G; Liu R
BMC Gastroenterol; 2022 Nov; 22(1):454. PubMed ID: 36371178
[TBL] [Abstract][Full Text] [Related]
38. Clinicopathological features, prognostic significance, and associated tumor cell functions of family with sequence similarity 111 member B in pancreatic adenocarcinoma.
Gong Q; Dong Q; Zhong B; Zhang T; Cao D; Zhang Y; Ma D; Cai X; Li Z
J Clin Lab Anal; 2022 Dec; 36(12):e24784. PubMed ID: 36408702
[TBL] [Abstract][Full Text] [Related]
39. CMTM6 is highly expressed in lung adenocarcinoma and can be used as a biomarker of a poor diagnosis.
Jia D; Xiong L; Xue H; Li J
PeerJ; 2023; 11():e14668. PubMed ID: 36643629
[TBL] [Abstract][Full Text] [Related]
40. Bioinformatics analysis identified MMP14 and COL12A1 as immune-related biomarkers associated with pancreatic adenocarcinoma prognosis.
Li Y; Su Z; Wei B; Qin M; Liang Z
Math Biosci Eng; 2021 Jun; 18(5):5921-5942. PubMed ID: 34517516
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
